Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Infinity Pharmaceuticals, Inc. Common Stock Intraday Chart
|Intraday||Last 52 Weeks|
|High||$ 6.20||$ 14.675|
|Low||$ 5.80||$ 4.75|
The current last sale of $5.97 is 25.68% Higher thanthe 52 week low.
Company Description (as filed with the SEC)
We are an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to patients with difficult-to-treat diseases. We combine proven scientific expertise with a passion for developing novel small molecule drugs that target disease pathways for potential applications in oncology. Our most advanced product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K, which is currently being evaluated for the treatment of hematologic malignancies, or blood cancers. We believe that duvelisib is the only inhibitor of PI3K-delta and gamma being investigated in Phase 3 clinical trials. We are pursuing duvelisib in oncology through a strategic collaboration with AbbVie Inc., or AbbVie. For information regarding our collaboration, please see below under the heading "AbbVie" in the section entitled "Strategic Alliances. ... More ...
Where does INFI fit in the risk graph?
Nasdaq Official Price
|Annual EPS Est:||$-2.62|
|Quarterly EPS Est:||-0.86|